Results 171 to 180 of about 723,030 (329)

MicroRNAs in seminal plasma are able to discern infertile men at increased risk of developing testicular cancer

open access: yesMolecular Oncology, EarlyView.
Male infertility is a known risk factor for the development of testicular cancer. In this paper, we analyzed the expression profile of a microRNA panel by real‐time PCR and validated the results by digital PCR. Experimental and bioinformatics analyses allowed us to identify possible biomarkers able to discern men with a higher risk of developing ...
Carmen Ferrara   +14 more
wiley   +1 more source

Genetic Engineering of Milk [PDF]

open access: bronze, 1990
Robert D. Bremel
openalex   +1 more source

Detection rate for ESR1 mutations is higher in circulating‐tumor‐cell‐derived genomic DNA than in paired plasma cell‐free DNA samples as revealed by ddPCR

open access: yesMolecular Oncology, EarlyView.
Analysis of ESR1 mutations in plasma cell‐free DNA (cfDNA) is highly important for the selection of treatment in patients with breast cancer. Using multiplex‐ddPCR and identical blood draws, we investigated whether circulating tumor cells (CTCs) and cfDNA provide similar or complementary information for ESR1 mutations.
Stavroula Smilkou   +11 more
wiley   +1 more source

Multi‐omics profiling reveals key factors involved in Ewing sarcoma metastasis

open access: yesMolecular Oncology, EarlyView.
Using a mouse model that recapitulates the spread of tumor cells within the body, we have profiled paired tumors and metastasis samples using a multiomics approach combining different layers of biological information. We identified key genes that drive metastasis in Ewing sarcoma.
Mariona Chicón‐Bosch   +11 more
wiley   +1 more source

The role of the university in genetic engineering

open access: yesCalifornia Agriculture, 1982
Not available – first paragraph follows:From a cursory glance at university and industry responsibilities, it would appear that the roles are clearly different, easily distinguished from one another. Unfortunately, this is not so.
J Lyons, C Hess
doaj  

Robust acute myeloid leukemia engraftment in humanized scaffolds using injectable biomaterials and intravenous xenotransplantation

open access: yesMolecular Oncology, EarlyView.
Patient‐derived xenografts (PDXs) can be improved by implantation of a humanized niche. We tested different biomaterials and approaches, and demonstrate that the combination of an injectable biomaterial for scaffold creation plus an intravenous route for acute myeloid leukemia (AML) xenotransplantation provide the most convenient and robust approach to
Daniel Busa   +13 more
wiley   +1 more source

Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer

open access: yesMolecular Oncology, EarlyView.
This study employed targeted metabolomic profiling to identify 302 distinct metabolites present in platelet‐rich plasma (PRP), revealing aberrant metabolic profiles amongst individuals diagnosed with colorectal cancer (CRC). Compared to carcinoembryonic antigen (CEA) and cancer antigen 19‐9 (CA199), our metabolite panel showed improved sensitivity ...
Zuojian Hu   +7 more
wiley   +1 more source

"Going back to our roots": second generation biocomputing

open access: yes, 2005
Researchers in the field of biocomputing have, for many years, successfully "harvested and exploited" the natural world for inspiration in developing systems that are robust, adaptable and capable of generating novel and even "creative" solutions to ...
Amos, Martyn   +3 more
core  

KMT2A degradation is observed in decitabine‐responsive acute lymphoblastic leukemia cells

open access: yesMolecular Oncology, EarlyView.
We demonstrate that decitabine (DEC) not only degrades the DNA methyltransferase DNMT1 but also the leukemic driver lysine methyltransferase KMT2A likely due to structural similarity of the DNA‐binding CXXC domains. DEC influences KMT2A downstream processes and synergizes with menin inhibitor revumenib (REV) to decrease leukemic cell proliferation, and
Luisa Brock   +10 more
wiley   +1 more source

Home - About - Disclaimer - Privacy